KEYNOTE-427 cohort B: First-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma

Bookmark and Share
Published: 19 Feb 2019
Views: 1213
Rating:
Save
Prof David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Prof David McDermott speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about results from cohort B of the KEYNOTE-427 study looking at first-line pembrolizumab monotherapy for advanced non-clear cell renal cell carcinoma.

He explains that, compared to clear cell patients, non-clear cell patients don't tend to have many therapies available and have been excluded from most of the immune therapy trials due to a historically poor response to cytokine therapy.

Prof McDermott reports activity was seen and that there was an overall response of 25% with particular favourability in the papillary and unclassified histology groups.